TrialFrontiers in endocrinology2024

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Sophie Leboulleux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.